ReviewMediators of inflammation2015
Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored.
Review in Mediators of inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of CD1 and FcγR gene polymorphisms with Guillain-Barré syndrome susceptibility: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018Pooled it
- Results From a Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ANX005, a C1q Inhibitor, in Patients With Guillain-Barré Syndrome.Journal of the peripheral nervous system : JPNS · 2025Trial
- Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants.Scientific reports · 2019Trial
- Guillain-Barré syndrome and albuminocytological dissociation: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Neurofilament Light Chain Levels as Diagnostic and Prognostic Biomarkers in Guillain-Barré Syndrome: An Updated Systematic Review and Meta-Analysis.Neurology and therapy · 2025Article
- Correlation between Electrodiagnostic Findings and Cerebrospinal Fluid Changes in Children with Guillain-Barre syndrome.Iranian journal of child neurology · 2025Article
- A Comprehensive Description of the Roadmap to Identify and Validate a Myelin Biomarker.Biomarker insights · 2025Article
- The Impact of COVID-19 on the Guillain-Barré Syndrome Incidence.Biomedicines · 2024Review
- Increased Cerebrospinal Fluid Adenosine 5'-Triphosphate Levels in Patients with Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy.Neurology research international · 2024Article
- Review
- Article
- Elevated monocyte to high-density lipoprotein cholesterol ratio correlates with clinical severity in acute inflammatory demyelinating polyradiculoneuropathy patients.Frontiers in neurology · 2022Article
- Elevated cerebrospinal fluid levels of beta-2-microglobulin in patients with Guillain-Barré syndrome and their correlations with clinical features.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS.Journal of neurology, neurosurgery, and psychiatry · 2021Article
- Relationship between cerebrospinal fluid protein level and electrophysiologic abnormalities in the acute inflammatory demyelinating polyradiculoneuropathy variant of Guillain-Barré syndrome.German medical science : GMS e-journal · 2021Article
- Assessment of Expression ofFrontiers in immunology · 2021Article
- Case Report: Plasma Biomarkers Reflect Immune Mechanisms of Guillain-Barré Syndrome.Frontiers in neurology · 2021Article
- Cerebrospinal Fluid of Preeclamptic and Normotensive Pregnant Women Compared to Nonpregnant Women Analyzed with Mass Spectrometry.ACS omega · 2020Article
- Inferring immune-associated signatures based on a co-expression network in Guillain-Barré syndrome.Cell proliferation · 2019Article
- Peripheral Demyelinating Diseases: From Biology to Translational Medicine.Frontiers in neurology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guillain-Barré syndrome (GBS), the axonal subtype of which is mainly triggered by C. jejuni with ganglioside-mimicking lipooligosaccharides (LOS), is an immune-mediated disorder in the peripheral nervous system (PNS) accompanied by the disruption of the blood-nerve barrier (BNB) and the blood-cerebrospinal fluid barrier (B-CSF-B). Biomarkers of GBS have been extensively explored and some of them are proved to assist in the clinical diagnosis and in monitoring disease progression as well as in assessing the efficacy of immunotherapy. Herein, we systemically review the literature on biomarkers of GBS, including infection-/immune-/BNB, B-CSF-B, and PNS damage-associated biomarkers, aiming at providing an overview of GBS biomarkers and guiding further investigations. Furthermore, we point out further directions for studies on GBS biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.